Thursday, 15 October 2026European Markets

HØLAND OG SETSKOG Stock Bullish Momentum With A 9% Rise So Far Today

Loading stream...

(VIANEWS) - Shares of HØLAND OG SETSKOG (Oslo Børs All-share Index_GI: HSPG.OL) rose 9.86% to 156.00 kr at 13:39 EST on Monday, after five successive sessions in a row of losses. Oslo Børs All-share Index_GI is sliding 0.32% to 1,413.65 kr, after four consecutive sessions in a row of losses. This seems, up until now, a somewhat negative trend exchanging session today.

About HØLAND OG SETSKOG

Høland og Setskog Sparebank provides banking services for the retail and corporate markets in Norway. It offers deposits and loans, as well as insurance products. The company was formerly known as Holand Sparebank and changed its name to Høland og Setskog Sparebank in 2010. The company was founded in 1849 and is headquartered in Bjørkelangen, Norway.

Earnings Per Share

As for profitability, HØLAND OG SETSKOG has a trailing twelve months EPS of 77.15 kr.

PE Ratio

HØLAND OG SETSKOG has a trailing twelve months price to earnings ratio of 2.02. Meaning, the purchaser of the share is investing 2.02 kr for every norwegian krone of annual earnings.

Volume

Today's last reported volume for HØLAND OG SETSKOG is 1545 which is 1987.84% above its average volume of 74.

More news about HØLAND OG SETSKOG (HSPG.OL).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com